(TMO) Thermo Fisher Scientific - Ratings and Ratios

Thermo Fisher Scientific Inc. (NYSE:TMO) is a global leader in life sciences, offering a comprehensive portfolio of products and services across North America, Europe, Asia-Pacific, and other international markets. The company operates through four primary segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.

The Life Sciences Solutions segment provides reagents, instruments, and consumables for biological and medical research, drug and vaccine development, and disease diagnosis. The Analytical Instruments segment supplies instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and clinical research markets. The Specialty Diagnostics segment includes clinical diagnostics, microbiology, transplant diagnostics, and immunodiagnostics, offering kits, assays, and systems for disease monitoring and diagnosis. The Laboratory Products and Biopharma Services segment provides laboratory products, pharma services, and clinical research solutions.

Thermo Fisher Scientific distributes its products through a direct sales force, customer-service professionals, e-commerce platforms, and third-party distributors under brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Founded in 1956 and headquartered in Waltham, Massachusetts, the company plays a critical role in advancing scientific research, healthcare, and diagnostics. Web URL: https://www.thermofisher.com

Ticker Symbol: TMO | Exchange: NYSE | Type: common stock | Country Origin: United States | GICS Sub Industry: Life Sciences Tools & Services

3-Month Forecast: Based on and , TMO is expected to trade within a range of $390-$470. Support levels are anticipated at $410 and $435, with resistance at $455 and $480. The stocks current price of $427.50 is below its 20-day SMA of $469.30, indicating near-term weakness. However, its forward P/E of 18.80 and RoE of 12.79 suggest long-term stability. The ATR of 16.72 indicates moderate volatility, with potential upside driven by strong demand for life sciences tools and diagnostics.